GlassScriptPhysician profile
Nicholas Pennings
NPI 1982642096
$55,280.49
in general payments reported to CMS, 2019-2025
11 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $54.70 · 2021: $3,544 · 2022: $4,925 · 2023: $363 · 2024: $681 · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Consulting Fee: $13K · Food and Beverage: $1,774 · Travel and Lodging: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,195.94 |
| Consulting Fee | $12,738.75 |
| Food and Beverage | $1,773.52 |
| Travel and Lodging | $1,714.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $47,121.42 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Eli Lilly and Company | $7,556.66 | 2022-2025 | Zepbound |
| Lilly USA, LLC | $159.06 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $123.19 | 2024 | Breztri |
| Medtronic Minimed, INC. | $117.26 | 2019 | |
| Pfizer INC. | $56.18 | 2024 | |
| Janssen Pharmaceuticals, INC | $50.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.85 | 2024 | |
| Kvk-Tech, INC. | $21.39 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $17.77 | 2024 | Onzetra Xsail, Contrave |
| Cashflow Solutions, LLC | $12.71 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Pennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.